antiplatelet
美 [æn'tɪpleɪtlet] 
英 [æn'tɪpleɪtlet]
- adj.抗血小板的
- 网络抗血小板药物；冠心症治療的常用药物
英汉解释
例句
The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.
FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
The nanoparticles "hold immense potential to be promoted as an antiplatelet agent, " the researchers note.
研究者们指出“纳米粒子是一种极具潜力的抗血小板聚集制剂”。
Antiplatelet therapy is one of the important measures in the secondary prevention of ischemic stroke.
抗血小板治疗是缺血性卒中二级预防的重要措施之一。
They did not find nearly as strong a link between antiplatelet agents and ICH as that between anticoagulation and hemorrhages , she added.
她补充说，他们发现抗血小板药物与颅内出血发病之间的联系并不如抗凝剂与出血事件之间的联系那么紧密。
The authors recommended that intensified antiplatelet therapy might be indicated for type 2 diabetic patients.
作者建议强化抗血小板疗法可能会用于2型糖尿病患者。
Current therapies for arterial ischemic stroke include thrombolytic, antithrombotic and antiplatelet agents, blood transfusion and surgery.
目前治疗手段主要包括溶栓、抗凝、抗血小板、输血以及外科治疗。
The researchers found the risks of developing preeclampsia dropped 10 percent among women taking aspirin or other antiplatelet medications.
研究者发现，相比于服用阿司匹林或者其它抗血小板药物，患先兆子痫的概率下降了10%。
The search for a useful clinical laboratory diagnostic assay for the antiplatelet antibodies has been long and difficult.
探索有效的检测血小板抗体的临床实验方法经历了漫长和艰辛的过程。
Aspirin is an effective antiplatelet drug with proven benefit in the primary and secondary prevention of coronary heart disease.
研究背景：阿司匹林是冠心病一级预防和二级预防有效抗血小板药物。
The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy.
这个报道列出了多条实用的建议来减少早期停用抗血小板治疗。
Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events : More " Advanced " Drug, More Perfect ?
心血管事件的二级预防：抗血小板治疗药物越“先进”越完美吗？。
What are the factors that may guide the decision to select a specific antiplatelet agent to initiate first after ischemic stroke?
那么，在缺血性卒中后选择某一种特定药物开始抗血小板治疗时，需要考虑哪些因素？
Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.
抗血小板药物（例如波利维）被用来帮助预防伴心脏病人群中潜在有危险性的血栓形成。
Title: Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?
抗血小板预防可否减少肝移植术后肝动脉栓塞的发生率？。
New drugs and new technologies, especially antiplatelet and regulation of lipid metabolism are emerging and applying in clinical practice.
新药物和新技术不断出现，新药物和新技术不断出现，并应用于临床，尤其是抗血小板应用于临床，和调节脂质代谢方面
Clinical trial of antithrombotic therapy became the high points, some hopeful new antiplatelet drugs and anticoagulants made their debuts.
其中最令人关注的几项临床试验均涉及抗栓治疗，有希望的抗血小板和抗凝新药纷纷登台亮相。
These findings underscore the need of individualized antiplatelet treatment regimens in diabetic patients.
这些结果都强调了对于糖尿病患者抗血小板治疗方案的个体化需要。
Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.
长期与氯吡格雷抗血小板治疗是强制性植入后药物涂层支架。
Objective To assess the activity in blood clotting and antiplatelet aggregation of dragon blood from different habitats.
目的考察不同产地血竭在凝血和抗血小板聚集方面的作用。
On-TIME 2 is an important study that gives a number of insights into optimising the antiplatelet regimen in primary PCI.
TIME2是一项重要研究，它在PCI抗血小板治疗的优化上提供了更多证据。
International Circulation: Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?
《国际循环》：您能谈谈ACS患者早期抗血小板治疗的最佳策略选择吗？
Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.
目的观察质子泵抑制剂埃索美拉唑是否影响氯吡格雷的抗血小板聚集作用。
There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.
没有任何证据表明，抗血小板制剂降低心衰患者动脉粥样硬化的危险。
Cilostazol, the model drug of this study, is a synthetic antiplatelet agent with vasodilating effect.
此研究使用的模式药物为cilostazol，它是合成的抗凝血制剂并具有血管舒张的作用。
Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy.
而实际上，华法林比抗血小板治疗更加有效（大约40%）。
In patients at low risk of GI bleeding, however, the balance of risk and benefit tips away from using PPIs together with antiplatelet drugs.
然而，在处于胃肠道出血低度风险的患者中，风险和获益的平衡反对同时使用质子泵抑制剂和抗血小板药物。
Antiplatelet agents are not as effective as warfarin in reducing the risk of thromboembolism in patients with AF.
抗血小板制剂不能象华法林那样在房颤病中有效地减少血栓栓塞的危险。
Antiplatelet nonspecific antibody and neonatal platelets are more closely related to reduce rates, a statistically significant (P 05).
抗血小板非特异性抗体与新生儿血小板减少发生率关系更为密切，具有统计学意义（P0.05）。
So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder.
抗血小板治疗有助于减少心、脑血管不良事件的发生。
We speculate that in the later cohort clinicians were more aware of the risk of DES and prolonged antiplatelet therapy.
我们推测，在后来的队列研究中，临床医师更加重视DES的风险，并延长了抗血小板治疗时间。
But these antiplatelet drugs also increase the risk of bleeding, including upper GI bleeding.
但是这些抗血小板药物也增加出血的风险，包括上消化道出血。
Aspirin is the sole evidence-based antiplatelet drug for treatment of acute ischemic stroke.
阿司匹林是惟一经过循证医学证明有效并用于急性缺血性卒中的抗血小板药物。
Conclusions: Currently, eptifibatide is used as the adjunct antiplatelet agent in the majority of patients undergoing primary PCI.
结论——目前，在大多数接受PCI术后的患者中，替非罗班被用来作为抗血小板的辅助治疗。
Novel and more potent antiplatelet agents currently under clinical development will be useful in efforts to reach these therapeutic goals.
随着临床的发展，当前新型的以及更为有效的抗血小板剂将有助于达到这些治疗的效果。
Antiplatelet agents play a major role in thrombus prevention and cure.
抗血小板药物是最为重要的血栓防治药物。
In the future, antiplatelet therapy will likely be tailored for the individual patient, they note.
抗血小板治疗将来可能只会针对个别病人。
Among those with late and very late ST, the prevalence of dual-antiplatelet therapy was 57% and 36%, respectively.
在发生晚期和极晚期ST的患者中，双重抗血小板的应用比例分别占57%和36%。
In my opinion, it is not with triple therapy that we can solve this problem but with alternative antiplatelet agents.
我觉得，三重治疗并不能解决问题，而应该选择其他可选择的抗血小板药物。
Conclusion: Nearly 4 of 10 patients receiing warfarin management care were receiing warfarin and antiplatelet combination therapy.
结论：接受华法林治疗的患者中有约4成进行着华法林和抗血小板联合治疗。
Antiplatelet Therapy Necessary at Least a Year with Drug-Eluting Stents
药物洗脱支架至少需要抗血小板治疗一年
